

October 21, 2015

Dear Manufacturers,

I am writing on behalf of Truman Medical Center Hospital Hill (DSH260048) (“TMC HH”) and Truman Medical Center Lakewood (DSH260102) (“TMC LW”) to inform manufacturers that TMC HH and TMC LW recently underwent an audit by the Health Resources and Services Administration (HRSA) of their compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, TMC HH and TMC LW are qualified for the 340B Program as a Disproportionate Share Hospitals and have participated in the 340B Program as stated below.

Truman Medical Center Hospital Hill (DSH260048)	Start date: 12/01/1992
Truman Medical Center Lakewood (DSH260102)	Start date: 04/01/2001

Through the audit process, HRSA has found TMC HH and TMC LW non-compliant within their 340B Program and responsible for potential repayment as a result of the following finding(s):

TMCHH and TMCL dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B).

TMC HH and TMC LW have identified the affected manufacturers and have contacted each to notify them of these findings to begin a dialogue on appropriate repayment to affected manufacturers. If manufacturers have not received notification from TMC HH and TMC LW and believe repayment may be owed for the findings described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact me as noted below.

Sincerely,

K. Scott Zweerink, R.Ph.
System Director of Outpatient Prescription Services/340B Program Leadership
Truman Medical Center
2301 Holmes
Kansas City, Missouri 64108
816-404-3000